RxDoctor Payments Data

Janna Culpepper

Family · Scottsboro, ALNPI 1093866337

Payments from drug & device makers

$2,214in general payments, 2019–2025

Across 114 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$287
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$184
  • Otsuka America Pharmaceutical, Inc.$175
  • Teva Pharmaceuticals USA, Inc.$76
  • Corium, LLC$73
  • plus $258 from 11 others

What the payments were for

  • Food & beverage$2,214100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,214 in reported general payments places this provider in the 75th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$1,108
Medicare patients
31
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$79,501
EliquisApixaban72$69,367
XareltoRivaroxaban58$42,916
TrulicityDulaglutide40$39,800
EntrestoSacubitril/Valsartan55$24,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$20,462
SymbicortBudesonide/Formoterol Fumarate16$5,837
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen324$4,450
Albuterol Sulfate HfaAlbuterol Sulfate76$4,240
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,209
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen140$2,623
Metoprolol Succinate171$2,232
Amlodipine Besylate266$1,957
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide68$1,563
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$1,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$79,50172 claims
PfizerEliquis$11$69,36772 claims
AstraZenecaSymbicort$18$5,83716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,415 family providers in Alabama.

Other family in Scottsboro

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →